NASDAQ · Financial Statements

Cytosorbents Corporation (CTSO) Revenue, Earnings & Financial Statements

$4.52 NASDAQ: CTSO Market Cap $14.24M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Cytosorbents Corporation most recently reported annual revenue of $37.0M, a net loss of $8.0M. Revenue declined at an average annual rate of 1.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Cytosorbents Corporation: Revenue rose from $8.0M in 2016 to $37.0M in 2025, a change of +362.5% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -140.0% to -38.4%, a shift of +101.6 percentage points; the most recent year shows a net loss of $8.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$8.0M$13.0M$20.0M$23.0M$39.0M$40.0M$35.0M$31.0M$36.0M$37.0M
Operating Expenses$20.0M$23.0M$36.0M$42.0M$50.0M$63.0M$66.0M$63.0M$52.0M$51.0M
Operating Profit−$11.0M−$10.0M−$16.0M−$19.0M−$10.0M−$23.0M−$32.0M−$32.0M−$16.0M−$14.0M
Operating Margin-140.0%-73.5%-77.0%-83.3%-26.3%-56.7%-90.9%-102.8%-46.2%-38.4%
Other Income−$1.0M$1.0M−$2.0M−$1.0M$1.0M−$3.0M−$2.0M$2.0M−$6.0M$6.0M
Interest$0$1.0M$1.0M$1.0M$1.0M$0$0$0$1.0M$3.0M
Depreciation$0$0$0$1.0M$1.0M$1.0M$1.0M$2.0M$2.0M$2.0M
Profit Before Tax−$12.0M−$9.0M−$18.0M−$20.0M−$9.0M−$25.0M−$34.0M−$30.0M−$22.0M−$9.0M
Tax rate (%)2.6%7.4%3.5%5.4%12.6%2.9%3.2%2.7%7.5%4.7%
Net Profit−$12.0M−$8.0M−$17.0M−$19.0M−$8.0M−$25.0M−$33.0M−$29.0M−$21.0M−$8.0M
EPS−$9.40−$6.20−$11.20−$12.00−$4.00−$11.40−$15.00−$13.00−$7.60−$2.60

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$7.0M$9.0M$9.0M$9.0M$9.0M$9.0M$10.0M$9.0M$9.0M$9.0M$10.0M$10.0M
Operating Expenses$17.0M$14.0M$12.0M$13.0M$13.0M$13.0M$13.0M$12.0M$13.0M$12.0M$12.0M$11.0M
Operating Profit−$10.0M−$5.0M−$4.0M−$4.0M−$4.0M−$4.0M−$4.0M−$3.0M−$4.0M−$3.0M−$3.0M−$1.0M
Operating Margin-131.2%-51.8%-40.4%-51.0%-44.2%-44.5%-37.6%-30.2%-42.0%-34.3%-27.4%-12.0%
Interest$0$0$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$7.0M−$6.0M−$4.0M−$2.0M−$10.0M−$1.0M$2.0M−$4.0M−$5.0M−$5.0M−$4.0M−$2.0M
Tax rate (%)11.7%0.0%0.0%0.0%17.7%0.0%0.0%11.2%0.0%0.0%0.0%0.0%
Net Profit−$6.0M−$6.0M−$4.0M−$2.0M−$8.0M−$1.0M$2.0M−$3.0M−$5.0M−$5.0M−$4.0M−$2.0M
EPS−$2.60−$2.20−$1.53−$0.86−$2.80−$0.49$0.58−$1.00−$1.75−$1.60−$1.40−$0.58

Over the 10 years reported for Cytosorbents Corporation, borrowings increased from $5.0M in 2016 to $29.0M in 2025, cash stood at $6.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.10 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$10.0M$24.0M$33.0M$27.0M$90.0M$90.0M$63.0M$53.0M$47.0M$44.0M
Current Assets$8.0M$21.0M$28.0M$21.0M$82.0M$64.0M$34.0M$26.0M$22.0M$21.0M
Cash$5.0M$17.0M$22.0M$12.0M$71.0M$52.0M$22.0M$14.0M$3.0M$6.0M
Inventory$1.0M$1.0M$1.0M$2.0M$3.0M$5.0M$3.0M$4.0M$3.0M$5.0M
Receivables$1.0M$2.0M$4.0M$4.0M$5.0M$5.0M$6.0M$6.0M$7.0M$8.0M
Fixed Assets$1.0M$1.0M$2.0M$3.0M$3.0M$19.0M$23.0M$22.0M$21.0M$19.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$2.0M$2.0M$1.0M$0$2.0M
Other Assets$0$0$0$0$0$0$0$0$0$3.0M
Total Liabilities$10.0M$14.0M$16.0M$24.0M$11.0M$27.0M$28.0M$30.0M$36.0M$38.0M
Current Liabilities$6.0M$8.0M$7.0M$10.0M$10.0M$14.0M$10.0M$15.0M$10.0M$10.0M
Borrowings$5.0M$10.0M$10.0M$17.0M$1.0M$14.0M$18.0M$18.0M$27.0M$29.0M
Other Liabilities$5.0M$4.0M$6.0M$7.0M$10.0M$13.0M$10.0M$12.0M$9.0M$9.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$0$10.0M$17.0M$3.0M$79.0M$63.0M$35.0M$23.0M$11.0M$6.0M

For Cytosorbents Corporation, operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $13.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$7.0M−$6.0M−$11.0M−$17.0M−$6.0M−$14.0M−$28.0M−$22.0M−$14.0M−$12.0M
Investing Cash Flow$1.0M−$3.0M−$3.0M−$3.0M−$3.0M−$9.0M−$13.0M−$2.0M−$1.0M−$1.0M
Financing Cash Flow$0$2.0M$3.0M$3.0M$1.0M$0$0$0−$1.0M$0
Net Cash Flow$0$12.0M$5.0M−$10.0M$59.0M−$18.0M−$30.0M−$8.0M−$6.0M−$2.0M
Free Cash Flow−$7.0M−$8.0M−$12.0M−$18.0M−$7.0M−$18.0M−$35.0M−$23.0M−$15.0M−$13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-3.38
FCF Yield-52.90%
Quick Ratio0.44
Interest Coverage-6.50
Return 1Y-63.44%
Return 3Y-80.98%
Return 5Y-95.75%

Cytosorbents Corporation (CTSO) financials — frequently asked questions

What is Cytosorbents Corporation's annual revenue?

Cytosorbents Corporation (CTSO) reported annual revenue of $37.0M in its most recent fiscal year.

What is Cytosorbents Corporation's net profit?

Cytosorbents Corporation (CTSO) reported a net loss of $8.0M in its most recent fiscal year.

What is CTSO EV/EBITDA?

Cytosorbents Corporation's enterprise value to EBITDA (EV/EBITDA) ratio is -3.38. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Devices stocks

ABT revenue $44.3BISRG revenue $10.1BMDT revenue $36.4BSYK revenue $25.1BBSX revenue $20.1BEW revenue $6.1BRMD revenue $5.7BDXCM revenue $4.7BPHG revenue $17.8BZBH revenue $8.2BAll Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
CTSO Overview CTSO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.